公开(公告)号：US20070118405A1

公开(公告)日：2007-05-24

申请号：US11616945

申请日：2006-12-28

申请人： Robert Campbell ,  Stephen Gemmell ,  Marc Vogt ,  John Garibotto ,  Luis Malave ,  Deborah Cate-Brown ,  Aaron Oppenheimer ,  Christina Vivona ,  Pamela Mandler ,  David Frey

发明人： Robert Campbell ,  Stephen Gemmell ,  Marc Vogt ,  John Garibotto ,  Luis Malave ,  Deborah Cate-Brown ,  Aaron Oppenheimer ,  Christina Vivona ,  Pamela Mandler ,  David Frey

IPC分类号： G06Q10/00

CPC分类号： A61M5/172 ,  A61B5/14532 ,  A61B2560/0223 ,  A61B2562/0295 ,  A61M5/14248 ,  A61M2205/3569 ,  A61M2205/3592 ,  A61M2209/01 ,  A61M2230/201 ,  G06Q50/22 ,  G16H40/40

摘要： A control system for controlling an infusion pump, including interface components for allowing a user to receive and provide information, a processor connected to the user interface components and adapted to provide instructions to the infusion pump, and a computer program having setup instructions that cause the processor to enter a setup mode upon the control system first being turned on. In the setup mode, the processor prompts the user, in a sequential manner, through the user interface components to input basic information for use by the processor in controlling the infusion pump, and allows the user to operate the infusion pump only after the user has completed the setup mode.

摘要翻译： 一种用于控制输注泵的控制系统，包括用于允许用户接收和提供信息的接口部件，连接到用户接口部件并适于向输注泵提供指令的处理器，以及具有设置指令的计算机程序， 处理器在首先打开控制系统时进入设置模式。 在设置模式下，处理器以顺序的方式通过用户界面组件提示用户输入基本信息供处理器在控制输液泵中使用，并且允许用户仅在使用者具有 完成设置模式。

公开(公告)号：US20070088414A1

公开(公告)日：2007-04-19

申请号：US11442516

申请日：2006-05-25

申请人： Robert Campbell ,  Kevin Dolan ,  Wendy Woodley

发明人： Robert Campbell ,  Kevin Dolan ,  Wendy Woodley

IPC分类号： A61F2/00

CPC分类号： A61K9/127 ,  A61K9/0019 ,  A61K9/0021 ,  A61K9/1271 ,  A61K9/1275 ,  B82Y5/00 ,  B82Y10/00

摘要： The present invention relates to formulations, methods and devices for delivering one or more biologically active agents, particularly a diagnostic or therapeutic agent to the intradermal compartment of a subject's skin. The present invention provides an improved method of delivery of biologically active agents in that it provides among other benefits, rapid uptake into the local lymphatics, improved targeting to a particular tissue, improved bioavailability, improved tissue bioavailability, improved tissue specific kinetics, improved deposition of a pre-selected volume of the agent to be administered. This invention provides methods for rapid transport of agents through lymphatic vasculature accessed by intradermal delivery of the agent. Methods of the invention are particularly useful for delivery of diagnostic and therapeutic agents. The invention relates to the synergy gained in diagnosing and treating disease when intradermal delivery and controlled release materials are combined. Specifically, the synergy is achieved when intradermal delivery is combined with lipid based particles.

摘要翻译： 本发明涉及用于将一种或多种生物活性剂，特别是诊断或治疗剂递送到受试者皮肤的真皮内隔室的制剂，方法和装置。 本发明提供了递送生物活性剂的改进方法，因为它提供了其他益处，快速摄入局部淋巴管，改善对特定组织的靶向，改善的生物利用度，改善的组织生物利用度，改善的组织特异性动力学，改善的沉积 预先选定体积的待施用的药剂。 本发明提供了通过皮内递送试剂获得的通过淋巴脉管系统快速转运药剂的方法。 本发明的方法对于递送诊断和治疗剂特别有用。 本发明涉及当皮内递送和控制释放材料组合时在诊断和治疗疾病中获得的协同作用。 具体地，当皮内递送与基于脂质的颗粒结合时，实现协同作用。

公开(公告)号：US20060088889A1

公开(公告)日：2006-04-27

申请号：US11298344

申请日：2005-12-09

申请人： Perry Haaland ,  Douglas Sherman ,  Robert Campbell ,  Walter Stewart ,  Sheila Lloyd ,  Bruce Erickson ,  Ann Erickson

发明人： Perry Haaland ,  Douglas Sherman ,  Robert Campbell ,  Walter Stewart ,  Sheila Lloyd ,  Bruce Erickson ,  Ann Erickson

IPC分类号： C40B30/06 ,  C40B40/10

CPC分类号： C07K7/06 ,  C07K1/047 ,  C07K5/1008 ,  C07K5/101 ,  C07K5/1013 ,  C07K5/1019 ,  C07K5/1021 ,  C40B30/06

摘要： The present invention provides peptides libraries which are useful for rapid identification of biologically active compounds. The invention further provides peptides which include cell-growth affecting peptides and peptides which enhance or inhibit production of cellular proteins. Many of the peptides of the invention may be produced in large quantity by recombinant techniques and formulated in culture medium to produce the desired effect on cultured cells and tissues. Certain of the libraries of the invention and the peptides identified in them are particularly useful in concatemer-based recombinant expression methods.

摘要翻译： 本发明提供了可用于快速鉴定生物活性化合物的肽文库。 本发明还提供了包括增强或抑制细胞蛋白产生的细胞生长影响肽和肽的肽。 本发明的许多肽可以通过重组技术大量生产并配制在培养基中以对培养的细胞和组织产生所需的效果。 本发明的某些文库和其中鉴定的肽在基于连接体的重组表达方法中特别有用。

公开(公告)号：US20050255121A1

公开(公告)日：2005-11-17

申请号：US11006422

申请日：2004-12-06

申请人： Robert Campbell ,  Kevin Dolan ,  Wendy Woodley

发明人： Robert Campbell ,  Kevin Dolan ,  Wendy Woodley

IPC分类号： A61K31/716 ,  A61K39/00

CPC分类号： A61K9/0021 ,  A61K39/12 ,  A61K39/145 ,  A61K39/39 ,  A61K2039/54 ,  A61K2039/55555 ,  A61K2039/55583 ,  A61K2039/70 ,  C12N2760/16134 ,  C12N2760/16234 ,  Y02A50/386

摘要： The present invention relates to dermal vaccine formulations, designed for targeted delivery of an immunogenic composition to a dermal compartment of skin including the intradermal and epidermal compartments. The dermal vaccine formulations of the invention comprise an antigenic or immunogenic agent, and at least one molecule, e.g., a chemical agent, which enhances the presentation and/or availability of the antigenic or immunogenic agent to the immune cells of the intradermal compartment or epidermal compartment resulting in an enhanced immune response. The dermal vaccine formulations of the invention have enhanced efficacy as the antigenic or immunogenic agent is delivered to the intradermal compartment or epidermal compartment with enhanced presentation and/or availability to the immune cells that reside therein. The enhanced efficacy of the dermal vaccine formulations results in a therapeutically effective immune response after a single intradermal or epidermal dose, with lower doses of antigenic or immunogenic agent than conventionally used, and without the need for booster immunizations.

摘要翻译： 本发明涉及真皮疫苗制剂，其设计用于将免疫原性组合物靶向递送至包括皮内和表皮隔层的皮肤皮肤隔室。 本发明的真皮疫苗制剂包含抗原或免疫原性试剂和至少一种分子，例如化学试剂，其增强抗原或免疫原性试剂对皮内隔室或表皮的免疫细胞的呈递和/或可用性 隔室导致增强的免疫应答。 本发明的真皮疫苗制剂具有增强的功效，因为将抗原性或免疫原性药物递送至真皮内室或表皮隔室，其中存在于其中的免疫细胞具有增强的呈递和/或可用性。 真皮疫苗制剂的增强功效在单次真皮内或表皮剂量后产生治疗有效的免疫应答，其具有比常规使用的更低剂量的抗原性或免疫原性剂量，并且不需要加强免疫。

公开(公告)号：US20050244921A1

公开(公告)日：2005-11-03

申请号：US10209208

申请日：2002-07-29

申请人： Roger Tsien ,  Robert Campbell ,  Geoffrey Baird

发明人： Roger Tsien ,  Robert Campbell ,  Geoffrey Baird

IPC分类号： G01N21/78 ,  C07K14/435 ,  C07K19/00 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12N15/12 ,  C12N15/64 ,  C12N15/65 ,  C12Q1/02 ,  C12Q1/25 ,  G01N21/64 ,  G01N33/52 ,  G01N33/58 ,  G01N33/84 ,  C07H21/04 ,  C12P21/06

CPC分类号： C12Q1/25 ,  C07K14/43595 ,  G01N33/585 ,  G01N33/84 ,  G01N2500/02

摘要： The present invention relates generally to variant fluorescent proteins, and more specifically to monomeric and dimeric forms of Anthozoan fluorescent proteins. In one aspect, the present invention provides variants of fluorescent proteins, where the variants have a reduced propensity to tetramerize, and form dimeric or monomeric structures. The invention also relates to methods of making and using such fluorescent protein monomers and dimers.

摘要翻译： 本发明一般涉及变体荧光蛋白，更具体地涉及Anthozoan荧光蛋白的单体和二聚形式。 在一个方面，本发明提供荧光蛋白的变体，其中变体具有降低的四聚体倾向并形成二聚体或单体结构。 本发明还涉及制备和使用这种荧光蛋白单体和二聚体的方法。

公开(公告)号：US20050152873A1

公开(公告)日：2005-07-14

申请号：US11002678

申请日：2004-12-03

申请人： Robert Campbell ,  John Mikszta

发明人： Robert Campbell ,  John Mikszta

IPC分类号： A61K39/00 ,  A61K39/02 ,  A61K39/118 ,  A61K39/12 ,  A61K39/39 ,  A61K39/395 ,  A61K47/48 ,  A61P37/02 ,  C07K16/12 ,  C12P21/08 ,  A61K31/704 ,  A61K39/38 ,  A61K48/00

CPC分类号： C07K16/125 ,  A61K39/118 ,  A61K39/39 ,  A61K39/39541 ,  A61K2039/55516 ,  A61K2039/55561 ,  A61K2039/55577 ,  A61K2300/00

摘要： The invention relates to an immunogenic composition and methods of making and using the composition. The immunogenic composition contains a directing molecule, a stimulant and an immunogen. The stimulant and directing molecule are chemically distinct. The stimulant and immunogen are present in relative amounts to result in an improved immune response relative to that resulting from the immunogen and just one of the directing molecule or stimulant.

摘要翻译： 本发明涉及免疫原性组合物和制备和使用该组合物的方法。 免疫原性组合物含有指导分子，兴奋剂和免疫原。 兴奋剂和引导分子在化学上是不同的。 兴奋剂和免疫原以相对的量存在，导致相对于由免疫原产生的仅一种引导分子或兴奋剂的免疫应答的改善。

公开(公告)号：US20050123550A1

公开(公告)日：2005-06-09

申请号：US10842922

申请日：2004-05-10

申请人： Philippe Laurent ,  Robert Campbell ,  Ge Jiang ,  Vince Sullivan ,  Kevin Mar ,  Kevin Dolan

发明人： Philippe Laurent ,  Robert Campbell ,  Ge Jiang ,  Vince Sullivan ,  Kevin Mar ,  Kevin Dolan

IPC分类号： A61K20060101 ,  A61K31/716 ,  A61K39/00 ,  A61K35/78

CPC分类号： A61K9/0021 ,  A61K39/12 ,  A61K39/145 ,  A61K39/39 ,  A61K2039/54 ,  A61K2039/55555 ,  A61K2039/55583 ,  A61K2039/70 ,  C12N2760/16134 ,  C12N2760/16234 ,  Y02A50/386

摘要： The present invention relates to dermal vaccine formulations, designed for targeted delivery of an immunogenic composition to a dermal compartment of skin including the intradermal and epidermal compartments. The dermal vaccine formulations of the invention comprise an antigenic or immunogenic agent, and at least one molecule, e.g., a chemical agent, which enhances the presentation and/or availability of the antigenic or immunogenic agent to the immune cells of the intradermal compartment or epidermal compartment resulting in an enhanced immune response. The dermal vaccine formulations of the invention have enhanced efficacy as the antigenic or immunogenic agent is delivered to the intradermal compartment or epidermal compartment with enhanced presentation and/or availability to the immune cells that reside therein. The enhanced efficacy of the dermal vaccine formulations results in a therapeutically effective immune response after a single intradermal or epidermal dose, with lower doses of antigenic or immunogenic agent than conventionally used, and without the need for booster immunizations.

公开(公告)号：US20050119465A1

公开(公告)日：2005-06-02

申请号：US10493540

申请日：2002-10-22

申请人： William Brondyk ,  Xuliang Jiang ,  Robert Campbell

发明人： William Brondyk ,  Xuliang Jiang ,  Robert Campbell

IPC分类号： C12N15/09 ,  A61K38/00 ,  A61K38/24 ,  A61K47/48 ,  A61P15/08 ,  C07K20060101 ,  C07K14/59 ,  C12N5/00 ,  C12N5/10 ,  C12N15/16 ,  C12N15/63 ,  C12P21/00 ,  C12P21/02

CPC分类号： C07K14/59 ,  A61K38/00

摘要： The inventors have designed novel FSH mutants with increased glycosylation and longer half-lives for use in inducing folliculogenesis in human patients. The use of a FSH mutant preparation of the invention permits the use of lower cumulative doses of FSH to achieve the same or better clinical result.

摘要翻译： 本发明人设计了具有增加的糖基化和更长半衰期的新型FSH突变体用于诱导人类患者的卵泡发生。 使用本发明的FSH突变体制剂允许使用较低累积剂量的FSH来实现相同或更好的临床结果。

公开(公告)号：US20050107963A1

公开(公告)日：2005-05-19

申请号：US10506396

申请日：2003-03-03

申请人： Robert Campbell

发明人： Robert Campbell

IPC分类号： G05B17/02 ,  G05B23/02 ,  G01L1/00

CPC分类号： G05B17/02

摘要： A method for assessing the integrity of a structure, comprising the steps of: i) collecting data relating to the initial dimensions of the structure, ii) creating a computer model of the structure, iii) collecting data relating to the estimated load on the structure, iv) analysing the structure, using the computer model of the structure and the load data, in order to define areas which are subject to relatively high stress, v) measuring, after a time interval, the dimensions of the structure in high stress areas, vi) updating the computer model of the structure, using the results of step v), re-analysing the structure, using the updated computer model and the load data, in order to calculate a value for the integrity of the structure.

摘要翻译： 一种用于评估结构的完整性的方法，包括以下步骤：i）收集与结构的初始尺寸相关的数据，ii）创建该结构的计算机模型，iii）收集与该结构上的估计负载有关的数据 iv）使用结构和负荷数据的计算机模型分析结构，以便界定受到相对较高应力的区域，v）在时间间隔之后测量高应力区域中结构的尺寸 ，vi）使用步骤v）的结果更新计算机模型，使用更新的计算机模型和负载数据重新分析结构，以便计算结构的完整性的值。

公开(公告)号：US06842966B1

公开(公告)日：2005-01-18

申请号：US10651861

申请日：2003-08-29

申请人： Robert Campbell ,  Dana John Hassan ,  James Joseph Misner ,  Russell Clint Proctor

发明人： Robert Campbell ,  Dana John Hassan ,  James Joseph Misner ,  Russell Clint Proctor

IPC分类号： H02K5/14 ,  H02K5/167 ,  H02K15/14 ,  H02K5/16

CPC分类号： H02K15/14 ,  H02K5/148 ,  H02K5/1672 ,  H02K2205/06 ,  Y10T29/49009 ,  Y10T29/49011

摘要： An electric motor and method for reducing or eliminating end play. The motor comprises an adjustment member that cooperates with an end lamina member to facilitate reducing end play. The adjustment member is slidably mounted on an armature shaft and inside an aperture of a portion of the end lamina tube to reduce or eliminate end play. Thereafter, the adjustment member is permanently secured to the end lamina tube. In another illustrative embodiment, the movable bearing retainer sets endplay and also retains brushes in an open position prior to, for example, assembly of the motor.

摘要翻译： 一种用于减少或消除最终游戏的电动机和方法。 马达包括与端部薄片构件配合以便于减少最终游隙的调节构件。 调节构件可滑动地安装在电枢轴上并且在端部薄层管的一部分的孔内部，以减少或消除末端游隙。 此后，调节构件永久地固定在端板上。 在另一示例性实施例中，可移动轴承保持器在例如电动机的组装之前设置终端并且还将电刷保持在打开位置。